We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Almased Multi-Center Diabetes Intervention Trial (AMDIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01702012
Recruitment Status : Completed
First Posted : October 5, 2012
Last Update Posted : January 31, 2020
University of Freiburg
University of Campinas, Brazil
London Metropolitan University
University of Mysore
Information provided by (Responsible Party):
Wake Forest University Health Sciences

Brief Summary:

A 12 month multi-center randomization controlled study. Participants will be randomized to either a lifestyle education program or a meal replacement regimen with Almased, after an initial examination of eligibility criteria.

Primary outcome-HbA1c

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Obesity Dietary Supplement: Almased Meal Replacement Powder Behavioral: Group-Based Lifestyle Intervention Not Applicable

Detailed Description:
Age 21 + Male/Female gender Type 2 Diabetes Non-insulin dependent BMI 25-40 kg/m HbA1c 7.5-10%

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Evaluation of Almased on Glycemic Control and Metabolic Effects in Patients With Type 2 Diabetes
Actual Study Start Date : January 2013
Actual Primary Completion Date : April 2015
Actual Study Completion Date : May 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Almased Meal Replacement Powder
Participants assigned to this arm will receive the Almased meal replacement powder and will be asked to replace one meal per day during the first 6 months of participation. During the second 6 months, participants will be allowed to choose whether to continue using the product to replace a meal or to use the product as a supplement prior to meals.
Dietary Supplement: Almased Meal Replacement Powder
Commercially available meal replacement product that contains soy protein, honey, yogurt, and amino acids. Participants assigned to this arm will receive the Almased meal replacement product and will be asked to replace one meal per day during the first 6 month. During the second 6 months, they will be allowed to choose to continue using the Almased as a meal replacement or to use it as a supplement prior to meals.

Active Comparator: Lifestyle Intervention
Participants randomized to this group will receive 5 group sessions in the first two months of participation and 5 additional group sessions in the last two months. These group sessions will focus on lifestyle behavior changes for weight loss and management including goal-setting, calorie balance, general nutrition, and physical activity.
Behavioral: Group-Based Lifestyle Intervention

Primary Outcome Measures :
  1. Change in HbA1c (%) [ Time Frame: 2, 4, 6, 8, 10, and 12 months ]

Secondary Outcome Measures :
  1. Change in HOMA IR Index [ Time Frame: 2, 4, 6, 8, 10, and 12 months ]
    measure changes in Homeostasis Model of Insulin Resistance

  2. Change in fasting blood glucose (mg/dl) [ Time Frame: 2, 4, 6, 8, 10, and 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:• Gender: Men and women are eligible

  • Type 2 diabetes mellitus: Diabetes mellitus will be determined by medical records, current treatment, verification from personal health care provider, or test results meeting the 2010 American Diabetes Association criteria of fasting glucose ≥126 mg/dl, symptoms of hyperglycemia with casual plasma glucose > 200 mg/dl or two-hour plasma glucose ≥200 mg/dl after a 75 gram oral glucose load. Individuals who have a clinical history strongly suggestive of type 1 diabetes will be excluded. Individuals taking oral hypoglycemic medication with diet and exercise are eligible. Subjects taking insulin will not be eligible for entry into the study.
  • Body mass index: Overweight and obese individuals, with body mass index 25 - 40 kg/m2, are eligible. Weight loss is recommended for overweight diabetic participants with one or more cardiovascular risk factors.
  • Age: Individuals older than 21 years are eligible.
  • Ethnicity: All ethnic groups are eligible for the study.
  • Blood pressure: AMDIT will enroll individuals whose blood pressure is under at least moderate control. For safety purposes, moderate control will be defined in this study as systolic values under 160 mm/Hg and diastolic values under 100 mm/Hg. Individuals whose blood pressure exceeds these levels during screening will be advised to seek treatment and may be re-evaluated following initiation of antihypertensive treatment.
  • Glycemic control: AMDIT will enroll individuals whose HbA1c is between 7.5 and 10%. Individuals whose HbA1c exceeds this level may require more urgent care and will be told to seek treatment and may also be re-evaluated for inclusion.
  • Lipid control: Individuals with a fasting triglycerides concentration less than 500 mg/dl are eligible.
  • Willingness to participate: Participants must be willing to be randomized to either Almased or the Lifestyle Intervention and to follow the protocol to which they have been assigned. Individuals must be willing to modify their diet and their activity if they are assigned to the Lifestyle Intervention.

Exclusion Criteria:• Unable or unwilling to give informed consent or communicate with local study staff;

  • Psychotic disorders or bipolar disorders, hospitalization for depression in past six months;
  • Self-report of alcohol or substance abuse within the past twelve months, current consumption of more than 14 alcoholic drinks per week, and/or current acute treatment or rehabilitation program for these problems;
  • Plans to relocate to an area not served by AMDIT or travel plans that do not permit full participation in the study;
  • Known allergies to soy or dairy;
  • Current use of medications for weight loss;
  • Self-reported inability to walk two blocks;
  • History of bariatric surgery, small bowel resection, or extensive bowel resection;
  • Chronic treatment with systemic corticosteroids as weight gain associated with steroids may interfere with the intervention goals;
  • Candidates who have definite plans to move out of the area within the study period;
  • Candidates with any dietary practice, behavior, or attitude that would substantially limit adherence to the intervention;
  • Currently pregnant or nursing;
  • Cancer requiring treatment in the past five years, except for non-melanoma skin cancers or cancers that have clearly been cured or in the opinion of the investigator carry an excellent prognosis (e.g. Stage 1 cervical cancer);
  • HIV positive (self-report), due to effects on weight and body composition of HIV and medications used to treat HIV;
  • Active tuberculosis (self-report);
  • Cardiovascular or cardiopulmonary disease including a heart attack or procedure within the past three months; participation in a cardiac rehabilitation program within last three months; stroke or history/treatment for transient ischemic attacks in the past three months; documented history of pulmonary embolus in past six months; unstable angina pectoris or angina pectoris at rest; known history of cardiac arrest; known history of complex ventricular arrhythmia at rest or with exercise; known history of uncontrolled atrial fibrillation (heart rate of 100 beats per minute or more); known history of NYHA Class III or IV congestive heart failure; known history of acute myocarditis, pericarditis or hypertrophic myocardiopathy; known history of clinically significant aortic stenosis; known history of left bundle branch block or cardiac pacemaker unless evaluated by a cardiologist; cardiac defibrillator; heart transplant; known history of aortic aneurysm of at least 7 cm in diameter or aortic aneurysm repair;
  • Renal disease: urine dipstick protein of 4+ (equivalent to approximately > 1 g/day), serum creatinine exceeding 1.4 mg/dl (women) or 1.5 mg/dl (men), or currently receiving dialysis;
  • Known history of chronic obstructive pulmonary disease that would limit ability to follow the protocol;
  • Self-reported chronic hepatitis B or C or cirrhosis;
  • Inflammatory bowel disease requiring treatment in the past year;
  • Known history of Cushing's syndrome (clinic diagnosis or self-report);
  • Known history of Acromegaly (clinical diagnosis or self-report);
  • Amputation of lower limbs as result of non-traumatic causes;
  • Any major organ transplant (does not include cornea or hair transplants);
  • Conditions not specifically mentioned above may serve as criteria for exclusion at the discretion of the clinical site.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01702012

Layout table for location information
United States, North Carolina
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27157
Sponsors and Collaborators
Wake Forest University Health Sciences
University of Freiburg
University of Campinas, Brazil
London Metropolitan University
University of Mysore
Layout table for investigator information
Principal Investigator: Mara Z Vitolins, DrPH MPH RD Wake Forest University Health Sciences
Layout table for additonal information
Responsible Party: Wake Forest University Health Sciences
ClinicalTrials.gov Identifier: NCT01702012    
Other Study ID Numbers: IRB00020672
First Posted: October 5, 2012    Key Record Dates
Last Update Posted: January 31, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Wake Forest University Health Sciences:
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases